{"url_path":"/sec/imnn/8-k/2026-06-16/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 **","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-16","source_url":"https://www.sec.gov/Archives/edgar/data/749647/0001493152-26-028937-index.html","accession_number":"0001493152-26-028937","cik":"0000749647","ticker":"IMNN","issuer_name":"Imunon, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/749647/0001493152-26-028937-index.html","primary_entity_key":"0000749647","primary_entity_name":"Imunon, Inc."},"word_count":324,"has_tables":true,"body_markdown":"**Item\n5.07**\n**Submission\nof Matters to a Vote of Security Holders.**\n\n \n\nAs of the record\ndate for the determination of shareholders entitled to vote at the Meeting, there were 3,983,342 shares of the Company’s common\nstock outstanding and entitled to vote. At the Annual Meeting, 1,808,666 shares of the Company’s common stock were represented\nin person or by proxy, constituting a quorum. Set forth\nbelow are the matters acted upon at the Annual Meeting and the final voting results on each matter, each of which were described in the\nCompany’s Definitive Proxy Statement filed with the Securities and Exchange Commission on May 4, 2026.\n\n \n\n**Proposal\n1**\n\n \n\nThe\nCompany’s stockholders elected the individuals listed below as Class I directors of the Company’s board of directors until\nthe Company’s 2029 annual meeting of stockholders. The results of the vote were as follows:\n\n \n\nNominee\n \nFor\n \nWithheld\n \nBroker\nNon-Votes\n\nMr.\nFrederick J. Fritz\n \n647,890\n \n70,401\n \n1,090,375\n\nMs.\nChristine A. Pellizzari\n \n653,302\n \n64,989\n \n1,090,375\n\n \n\nIn\naddition to the directors elected above, Dr. Stacy R. Lindborg, Mr. Michael H. Tardugno, Mr. James E. Dentzer, and Dr. Donald P. Braun\ncontinued to serve as directors after the Annual Meeting.\n\n \n\n**Proposal\n2**\n\n \n\nThe\nCompany’s stockholders ratified the appointment of WithumSmith + Brown, PC as the independent registered public accounting firm\nfor the fiscal year ending December 31, 2026. The results of the vote were as follows:\n\n \n\nFor\n \nAgainst\n \nAbstain\n\n1,715,881\n \n81,399\n \n11,386\n\n \n\n**Proposal\n3**\n\n \n\nThe\nproposal to approve, on an advisory basis, the 2025 compensation of the Company’s named executive officers (“Say-on-Pay”),\nwas approved based upon the following votes:\n\n \n\nFor\n \nAgainst\n \nAbstain\n \nBroker\nNon-Votes\n\n580,096\n \n115,666\n \n22,529\n \n1,090,375\n\n \n\n**Proposal\n4**\n\n \n\nThe\nproposal to approve an Amendment to the IMUNON, INC. 2018 Stock Incentive Plan to increase the aggregate number of shares of common stock\nthat may be delivered pursuant to all awards granted under the Plan was approved based upon the following votes:\n\n \n\nFor\n \nAgainst\n \nAbstain\n \nBroker\nNon-Votes\n\n562,622\n \n137,055\n \n18,614\n \n1,090,375"}